PANTANO, FRANCESCO
 Distribuzione geografica
Continente #
AS - Asia 5.552
NA - Nord America 1.239
EU - Europa 554
SA - Sud America 49
AF - Africa 17
OC - Oceania 13
AN - Antartide 1
Totale 7.425
Nazione #
SG - Singapore 4.298
US - Stati Uniti d'America 1.169
CN - Cina 619
HK - Hong Kong 510
IT - Italia 143
GB - Regno Unito 131
DE - Germania 77
CA - Canada 44
IN - India 44
NL - Olanda 38
BR - Brasile 37
FI - Finlandia 23
JP - Giappone 20
MX - Messico 20
CZ - Repubblica Ceca 19
FR - Francia 18
TR - Turchia 18
ES - Italia 14
AU - Australia 12
PL - Polonia 12
UA - Ucraina 12
SE - Svezia 11
ZA - Sudafrica 11
AT - Austria 9
EE - Estonia 9
ID - Indonesia 9
VN - Vietnam 9
KR - Corea 7
RU - Federazione Russa 7
AR - Argentina 5
LT - Lituania 5
RO - Romania 4
SA - Arabia Saudita 4
BD - Bangladesh 3
BE - Belgio 3
DK - Danimarca 3
GR - Grecia 3
PT - Portogallo 3
CH - Svizzera 2
CL - Cile 2
DO - Repubblica Dominicana 2
LV - Lettonia 2
RS - Serbia 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BF - Burkina Faso 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CO - Colombia 1
EC - Ecuador 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
KZ - Kazakistan 1
MD - Moldavia 1
ML - Mali 1
MS - Montserrat 1
MY - Malesia 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
TH - Thailandia 1
TO - Tonga 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
YE - Yemen 1
Totale 7.425
Città #
Hong Kong 509
Hefei 330
Singapore 327
Ashburn 251
Boardman 172
Dallas 138
London 116
Shanghai 113
Beijing 109
Los Angeles 57
Munich 40
San Francisco 40
Rome 34
Amsterdam 25
Santa Clara 25
Council Bluffs 24
Pune 24
New York 21
Toronto 21
Brooklyn 20
Brno 18
Mexico City 17
Seattle 17
Redmond 16
Helsinki 14
Montreal 14
São Paulo 14
Washington 14
Chicago 12
Stockholm 10
Tokyo 10
Warsaw 10
Turku 9
Boston 8
Xi'an 8
Ankara 7
Canberra 6
Charlotte 5
Chennai 5
Denver 5
Hyderabad 5
Johannesburg 5
Las Vegas 5
Melbourne 5
Milan 5
Naples 5
Paris 5
Phoenix 5
Yeonsu-gu 5
Miami 4
New Delhi 4
Oklahoma City 4
Padova 4
Riyadh 4
Sona 4
Vienna 4
West Jordan 4
Athens 3
Atlanta 3
Capaccio 3
Copenhagen 3
Durham 3
Ho Chi Minh City 3
Manchester 3
Montesilvano Marina 3
Moscow 3
Ningbo 3
Pescara 3
Porto 3
Anyang 2
Buffalo 2
Caluire-et-Cuire 2
Charleston 2
Falkenstein 2
Ferrara di Monte Baldo 2
Genoa 2
Gragnano 2
Haikou 2
Haiphong 2
Juneau 2
Karthaus 2
Kragujevac 2
Lyon 2
Madrid 2
Miano 2
Mumbai 2
Nanjing 2
Oniferi 2
Prineville 2
Raleigh 2
Riga 2
Salt Lake City 2
San Jose 2
Santiago de los Caballeros 2
Scafati 2
Secaucus 2
The Dalles 2
Trieste 2
Vilnius 2
Wuhan 2
Totale 2.790
Nome #
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference? 223
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 215
Abstract 486: MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes 208
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence 207
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment 201
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases 199
A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation 197
Designing a broad-spectrum integrative approach for cancer prevention and treatment 196
Artificial Intelligence in Detection, Management, and Prognosis of Bone Metastasis: A Systematic Review 194
Premetastatic niche: ready for new therapeutic interventions? 192
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 170
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 167
BOMB trial: First results of stereotactic radiotherapy to primary breast tumor in metastatic breast cancer patients 121
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 115
'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer 108
Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center Experience 107
Subaxillary Replacement Flap Compared with the Round Block Displacement Technique in Oncoplastic Breast Conserving Surgery: Functional Outcomes of a Feasible One Stage Reconstruction 102
Anterior and posterior vaginal myomectomy: A new surgical technique 98
Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: Impact on breast cancer recurrence and survival 97
Preoperative Ultrasound-guided Sub-areolar Biopsy in Predicting Occult Nipple Involvement in Breast Cancer Patients: Proposal for a Methodological Approach 92
Biological effects of cabozantinib on bone microenvironment 92
Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis 91
Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series 91
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw 90
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 90
A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins 90
Biological effects of cabozantinib on osteosarcoma-bone microenvironment model 90
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 89
Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment 89
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 88
Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential 88
Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions 88
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. 87
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs). 86
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 85
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 83
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. 82
Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge 62
A Nanostring gene expression approach identifies aggressive clinical behavior related genes in dedifferentiated liposarcoma 44
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 42
Role of c-mesenchymal-epithelial transition pathway in gastric cancer 41
Molecular prognostic factors in patients with pancreatic cancer 35
Denosumab for cancer-related bone loss 35
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models 33
New targets, new drugs for metastatic bone pain: a new philosophy 33
Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms 33
Neutrophil-to-lymphocyte ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with nivolumab in pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study 31
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma 30
CETUXIMAB: From bench to bedside 30
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7) 29
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients 29
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients 29
Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone 29
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients 28
Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment 28
Interleukin 1ss-511T gene (IL1ss) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis 28
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 28
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 28
Targeting bone metastases starting from the preneoplastic niche: home sweet home 27
The role of bone microenvironment, vitamin D and calcium 27
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial 27
Regression of papillary thyroid cancer during nivolumab for renal cell cancer 27
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma 27
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging 27
Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in advanced leiomyosarcoma and angiosarcoma 27
Tissue invasion and metastasis: Molecular, biological and clinical perspectives. 26
Bone Health in Cancer Patients 26
Monoclonal antibodies 26
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 26
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 26
Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer 25
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients 25
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives 25
Olaratumab: PDGFR-alpha inhibition as a novel tool in the treatment of advanced soft tissue sarcomas 24
The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence 24
TUMORI NEUROENDOCRINI 24
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey 24
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 24
Targeting bone metastases: New drugs for new targets 24
miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes 24
Prognostic and predictive factors in pancreatic cancer 24
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis 23
Interventional radiologist's perspective on the management of bone metastatic disease 23
Dynamic changes of receptor activator of nuclear factor-κB expression in circulating tumor cells during denosumab predict treatment effectiveness in metastatic breast cancer 23
Emerging Therapeutic Targets in Osteoncology 23
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 23
Effects of cabozantinib on bone turnover markers in patients with metastatic renal cell carcinoma 23
Integrin alpha-5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 23
ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors 23
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib 23
Osteoporosis 2014 23
Natural history of skeletal disease in primary biliary cancers. National survey on behalf of GICO group (Gruppo Italiano Colangiocarcinoma – Onlus) 23
Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis 22
Cabozantinib affects osteosarcoma growth through a direct effect on tumor cells and modifications in bone microenvironment 22
Targeted therapies for bone metastases 22
Facing SARS-CoV-2 outbreak in immunotherapy era 22
Role of glyoxalase-1 in trabectedin-resistant myxoid liposarcoma 22
Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis 21
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients 21
Deregulation of dicer and mir-155 expression in liposarcoma 21
Totale 6.425
Categoria #
all - tutte 63.106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.106


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022328 0 0 9 1 89 4 8 1 12 1 3 200
2022/202363 2 1 0 1 4 3 7 15 1 3 23 3
2023/2024508 16 49 30 31 50 224 6 20 6 24 16 36
2024/20255.748 76 92 206 49 39 137 115 31 491 456 1.794 2.262
2025/2026909 484 226 199 0 0 0 0 0 0 0 0 0
Totale 7.556